According to the research paper, due to the vaccine in 16 young monkeys of the rhesus macaque species, the ability to fight the virus remained for 22 weeks.
Moderna’s COVID-19 vaccine and a second protein-based experimental vaccine have proved to be safe and effective in producing antibodies to fight the corona virus in early trials on children of a species of monkey, rhesus macaque. Research published on Tuesday in the journal ‘Science Immunology’ indicates that vaccines for children may prove to be an effective weapon in reducing the horrors of the epidemic.
Celie Permer of New York-Presbyterian CommonSky Children’s Hospital in the US said, “Safe and effective vaccines for young children will help limit the spread of COVID-19 because we know that, even if children are exposed to COVID-19, Be sick with the infection or asymptomatic, they can spread it.
Parmer said, “What is even more important is that many children became ill and many even died due to the infection. The restrictions imposed to prevent infection had many more negative effects on children. That’s why children are entitled to the vaccine to protect them from COVID-19.
According to the research paper, due to the vaccine in 16 young monkeys of the rhesus macaque species, the ability to fight the virus remained for 22 weeks. Researchers are conducting challenging studies this year to develop a potential long-term protective shield from the vaccine.
Professor Christina de Paris at the University of North Carolina in the US said, “We are looking at potential antibody levels by comparing adult macaques, however, only 30 micrograms of vaccine was given to children of macaques, compared to 100 micrograms for adults.” was.”
“In Moderna’s vaccine, we saw a strong ‘T’ cell response, which we know is important in limiting disease severity,” de Paris said.
Four weeks later the second dose was given
Under this study, the researchers vaccinated 16 children of macaques at the age of about two months by dividing them into two groups of eight and then vaccinated again four weeks later. He said that all animals were given a preclinical variant of the modern mRNA-based vaccine or a protein-based vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) in the US.
The mRNA-based vaccine instructs the body to produce a virus surface protein, also known as a spike protein. This allows human immune cells to recognize these proteins and produce antibodies as well as take other measures for immunization.
The NIAID vaccine is actually a spike protein that the immune system detects in a similar way. Researchers claim that after both vaccines, antibodies developed in young monkeys and a remarkable response of spike protein-specific T cells was revealed.
Also read- Is cow’s calf serum actually used in covaccine?
Also read- Video: Diabetes patients are more at risk than corona, may have to face these serious conditions